A group of researchers has discovered that the use of a particular drug that acts as an oral anticoagulant, dabigatran, can delay the appearance of Alzheimer’s disease in mice. The research was carried out by scientists from the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Rockfeller University of New York while the study was published in the Journal of the American College of Cardiology .
According to the researchers, long-term anticoagulation with dabigatran effectively slowed the progression of Alzheimer’s disease in mice during experiments. Marta Cortés Canteli, a researcher at the CNIC and one of the authors of the study, speaks of an “important progress” regarding effective treatments for Alzheimer’s disease.
To defeat this disease, according to the researcher, there will be a need for personalized therapies aimed at various and different processes that can contribute to the progression of the disease. Among the objectives there is, according to the researcher, cerebral circulation and precisely to treat the latter an oral anticoagulant such as dabigatran can have an effective approach for those Alzheimer’s patients who have a tendency to coagulation.
According to the researcher, in addition to other studies that will have to certify the beneficial action of this drug, there will also be a need to create new diagnostic tools to identify Alzheimer’s patients with a tendency to coagulation with greater precision and efficiency, and precisely this “will be an important research line in the coming years.”